OM-85 BV in pediatric recurrent respiratory tract infections: a cost-utility analysis.

Abstract

BACKGROUND:

Despite the growing evidence on efficacy, little is known regarding the cost-utility of Vaxom/Imocur (OM-85 BV) supplementation to decrease the probability of recurrent respiratory tract infections in OM-85 BV to reduce the incidence of recurrent respiratory tract infections in children.

METHODS:

A decision tree model was used to estimate the cost and quality-adjusted life-years (QALYs) of OM-85 BV in a patient aged 1-6 with a history of recurrent respiratory tract infections. Multiple sensitivity analyses were conducted to evaluate the robustness of the model. Cost-effectiveness was evaluated using the willingness-to-pay defined for Colombia of US$5180 per QALY. The time horizon defined was six months. Costs were estimated from a societal perspective.

RESULTS:

The expected annual cost per patient with OM-85 BV was US$843 and with placebo was US$1167. The QALYs per person estimated with OM-85 BV was 0.91 and with placebo was 0.89.

CONCLUSION:

In conclusion, our study shows that OM-85 BV is a cost-effective strategy to reduce the incidence of recurrent respiratory tract infections in children. Our study provides evidence that should be used by decision-makers to improve clinical practice guidelines.

• Authors: Jefferson Antonio Buendía, Diana Guerrero Patiño, Erika Fernanda Lindarte
• Journal: BMC pulmonary medicine (BMC Pulm Med) Vol. 22 Issue 1 Pg. 465 (Dec 06 2022) ISSN: 1471-2466 [Electronic] England
• PMID: 36474205 (Publication Type: Journal Article)
• Copyright: © 2022. The Author(s).

Topics

• Humans
• Child
• Cost-Benefit Analysis
• Colombia
• Respiratory Tract Infections (drug therapy)